Stockreport

‘Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology [Yahoo! Finance]

ASX LTD UNSP/ADR  (ASXFY) 
NASDAQ:AMEX Investor Relations: asx.com.au/about/investor-relations.htm
PDF results from its Phase III ZIRCON trial have been published in The Lancet Oncology, reporting that Telix's first-in-class investigational PET agent, TLX250-CDx (Zircaix® [Read more]